An observational retrospective study evaluating efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in hepatitis C virus genotype 1- infected patients with compensated cirrhosis and multiple comorbidities
Latest Information Update: 08 Jul 2017
Price :
$35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2017 New trial record